BriaCell Therapeutics (NASDAQ:BCTX) Issues Earnings Results, Misses Expectations By $0.14 EPS

BriaCell Therapeutics (NASDAQ:BCTX) posted its earnings results on Monday. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.14), Zacks reports.

BriaCell Therapeutics Trading Down 7.9 %

Shares of NASDAQ BCTX traded down $0.05 during trading on Monday, reaching $0.61. The company had a trading volume of 2,315,225 shares, compared to its average volume of 1,645,847. The stock has a market capitalization of $22.00 million, a PE ratio of -0.52 and a beta of 1.46. BriaCell Therapeutics has a twelve month low of $0.46 and a twelve month high of $5.97. The stock has a 50-day moving average price of $0.84 and a two-hundred day moving average price of $0.88.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $15.00 price target on shares of BriaCell Therapeutics in a research report on Thursday.

About BriaCell Therapeutics

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.